Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Plimack · SciRah

Researcher profile · Semantic Scholar

E. Plimack

Share profile

E. Plimack — researcher profile on SciRah

h-index: 75
Works: 442
Citations: 47K

Most-cited papers

Kidney Cancer, Version 3.2022
R. Motzer, E. Jonasch, N. Agarwal, A. Alva +32 more
2022The Journal of the National Comprehensive Cancer Network590 citations Open access
Semantic Scholar
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
T. Choueiri, T. Bauer, K. Papadopoulos, E. Plimack +8 more
2021Nature Medicine265 citations Open access
Semantic Scholar
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
T. Flaig, P. Spiess, M. Abern, N. Agarwal +34 more
2022The Journal of the National Comprehensive Cancer Network263 citations Open access
Semantic Scholar
Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
R. Motzer, D. McDermott, B. Escudier, M. Burotto +21 more
2022Cancer247 citations Open access
Semantic Scholar
Bladder Cancer, Version 3.2024.
Thomas W. Flaig, P. Spiess, M. Abern, Neeraj Agarwal +33 more
2024The Journal of the National Comprehensive Cancer Network226 citations
Semantic Scholar
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
E. Plimack, T. Powles, V. Stus, R. Gafanov +17 more
2023European Urology146 citations
Semantic Scholar
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
A. Balar, D. Castellano, P. Grivas, D. Vaughn +16 more
2022Annals of Oncology112 citations Open access
Semantic Scholar
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.
B. Rini, E. Plimack, V. Stus, T. Waddell +16 more
2021Journal of Clinical Oncology85 citations
Semantic Scholar
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
M. Atkins, Opeyemi A. Jegede, N. Haas, D. McDermott +16 more
2022Journal of Clinical Oncology69 citations Open access
Semantic Scholar
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and with an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
L. Albiges, N. Tannir, M. Burotto, D. McDermott +18 more
2021European Urology69 citations Open access
Semantic Scholar
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.
B. Rini, E. Plimack, V. Stus, R. Gafanov +16 more
2023Journal of Clinical Oncology65 citations
Semantic Scholar
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin or External Beam Radiation Therapy in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16–243 ADAPT-BLADDER Study
N. Hahn, M. O'Donnell, J. Efstathiou, M. Zahurak +37 more
2023European Urology58 citations Open access
Semantic Scholar
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
J. Bellmunt, R. de Wit, Y. Fradet, M. Climent +27 more
2022Clinical Cancer Research55 citations Open access
Semantic Scholar
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer
J. Damrauer, Wolfgang Beckabir, Jeff A. Klomp, Mi Zhou +13 more
2022Nature Communications53 citations Open access
Semantic Scholar
Treatment-Free Survival after Immune Checkpoint Inhibitor Therapy vs. Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
M. Regan, Opeyemi A. Jegede, Charlene M. Mantia, T. Powles +17 more
2021Clinical Cancer Research43 citations Open access
Semantic Scholar
A phase 2 trial of risk enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1)
D. Geynisman, P. Abbosh, E. Ross, M. Zibelman +15 more
2024Journal of Clinical Oncology42 citations Open access
Semantic Scholar
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)
J. Rosenberg, K. Ballman, S. Halabi, P. Atherton +17 more
2021Journal of Clinical Oncology41 citations Open access
Semantic Scholar
Bladder cancer, version 3.2020
T. Flaig, P. Spiess, N. Agarwal, R. Bangs +31 more
202040 citations
Semantic Scholar
661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
R. Motzer, N. Tannir, D. McDermott, M. Burotto +15 more
2021Annals of Oncology39 citations Open access
Semantic Scholar
A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): Interim analysis.
D. Geynisman, P. Abbosh, E. Ross, M. Zibelman +16 more
202134 citations
Semantic Scholar
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
J. Bedke, B. Rini, E. Plimack, V. Stus +17 more
2022European Urology33 citations
Semantic Scholar
A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN).
D. Geynisman, P. Abbosh, E. Ross, M. Zibelman +16 more
2023Journal of Clinical Oncology31 citations Open access
Semantic Scholar
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
T. Choueiri, T. Powles, M. Voss, E. Plimack +5 more
2023Future Oncology29 citations Open access
Semantic Scholar
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
B. Rini, M. Atkins, E. Plimack, D. Soulières +15 more
2021European Urology Oncology29 citations
Semantic Scholar
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors
M. Zibelman, A. MacFarlane, K. Costello, T. McGowan +17 more
2023Nature Communications27 citations Open access
Semantic Scholar
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
M. Atkins, Opeyemi A. Jegede, N. Haas, D. McDermott +16 more
2023Journal for ImmunoTherapy of Cancer27 citations Open access
Semantic Scholar
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
K. Zarrabi, E. Handorf, B. Miron, M. Zibelman +4 more
2022The Oncologist27 citations Open access
Semantic Scholar
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
M. Galsky, A. Balar, P. Black, M. Campbell +11 more
2021Journal for ImmunoTherapy of Cancer27 citations Open access
Semantic Scholar
Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).
R. Motzer, S. Tykodi, B. Escudier, S. Oudard +16 more
202027 citations
Semantic Scholar
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
H. Jang, G. Hostetter, A. MacFarlane, Zachary B. Madaj +23 more
2023Clinical Cancer Research26 citations Open access
Semantic Scholar
Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).
A. Necchi, J. Bedke, M. Galsky, N. Shore +6 more
2023Journal of Clinical Oncology26 citations
Semantic Scholar
First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.
P. O'Donnell, A. Balar, J. Vuky, D. Castellano +10 more
202125 citations
Semantic Scholar
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial
M. Atkins, E. Plimack, I. Puzanov, M. Fishman +10 more
2021European Journal of Cancer25 citations Open access
Semantic Scholar
The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study.
T. Bauer, T. Choueiri, K. Papadopoulos, E. Plimack +8 more
202123 citations
Semantic Scholar
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)
Marijo Bilusic, N. Toney, R. Donahue, S. Wróblewski +10 more
2022Prostate Cancer and Prostatic Diseases21 citations Open access
Semantic Scholar
KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).
M. Galsky, A. Necchi, N. Shore, E. Plimack +4 more
202121 citations
Semantic Scholar
Role of immunotherapy in localized muscle invasive urothelial cancer
J. Kaur, Woonyoung Choi, D. Geynisman, E. Plimack +1 more
2021Therapeutic Advances in Medical Oncology17 citations Open access
Semantic Scholar
The European Urology Commitment to Gender Equity and Diversity: Expanding Cognitive Diversity through Inclusivity at the Podium.
S. Psutka, T. Morgan, M. Albersen, J. Cornu +4 more
2021European Urology15 citations
Semantic Scholar
Patients’ Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19
C. Bergerot, J. Malhotra, P. Bergerot, E. Philip +16 more
2023The Oncologist14 citations Open access
Semantic Scholar
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
R. Madan, Marijo Bilusic, M. Stein, R. Donahue +17 more
2023The Oncologist14 citations Open access
Semantic Scholar
Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop
Elaine Chang, A. Apolo, R. Bangs, Stephanie Chisolm +17 more
2021Nature reviews. Urology14 citations
Semantic Scholar
Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma.
P. Ghatalia, E. Plimack
2020The Journal of the National Comprehensive Cancer Network14 citations Open access
Semantic Scholar
Comparative cost‐effectiveness of neoadjuvant chemotherapy regimens for muscle‐invasive bladder cancer: Results according to VESPER data
Daniel D. Joyce, K. Wymer, Vidit Sharma, J. Moriarty +6 more
2022Cancer13 citations
Semantic Scholar
Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma
Òscar Reig Torras, Akhilesh Mishra, A. Christie, Tiffani McKenzie +13 more
2021European Urology13 citations
Semantic Scholar
Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-Institutional Prospective Cohort Evaluation
L. Bukavina, Rashida Ginwala, M. Sindhani, M. Prunty +16 more
2023bioRxiv12 citations Open access
Semantic Scholar
Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.
N. Tannir, R. Motzer, L. Albiges, E. Plimack +16 more
202112 citations
Semantic Scholar
Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
Abhishek Tripathi, Yu-Hui Chen, D. Jarrard, N. Hahn +14 more
2022Journal of Clinical Oncology11 citations
Semantic Scholar
A Seat at the Table: The Correlation Between Female Authorship and Urology Journal Editorial Board Membership.
M. Prunty, S. Rhodes, Helen H. Sun, April Miller +6 more
2022European Urology Focus10 citations
Semantic Scholar
Association Between Baseline Body Mass Index and Survival in Men with Metastatic Hormone Sensitive Prostate Cancer: ECOG-ACRIN CHAARTED E3805
A. Morgans, Yu-Hui Chen, D. Jarrard, M. Carducci +13 more
2022The Prostate10 citations Open access
Semantic Scholar
Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC).
T. Choueiri, E. Plimack, T. Powles, M. Voss +5 more
2022Journal of Clinical Oncology9 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Powles×15
Invite
T. Powles — researcher profile on SciRah
T. Choueiri×13
Invite
T. Choueiri — researcher profile on SciRah
B. Rini×12
Invite
B. Rini — researcher profile on SciRah
D. Geynisman×12
Invite
D. Geynisman — researcher profile on SciRah

×11

Invite

D. McDermott — researcher profile on SciRah

Invite

H. Hammers — researcher profile on SciRah

Invite

H. Gurney — researcher profile on SciRah

Invite

M. Zibelman — researcher profile on SciRah

Invite

P. Ghatalia — researcher profile on SciRah

Invite

R. Perini — researcher profile on SciRah

Invite

M. Atkins — researcher profile on SciRah

Invite

S. George — researcher profile on SciRah